Malignant Pleural Effusion: Medical Approaches for Diagnosis and Management

Overview

Journal Tuberc Respir Dis (Seoul)

Specialty Pulmonary Medicine

Date 2014 Jun 13

PMID 24920947

Citations 25

Authors

Hae-Seong Nam

Affiliations

Soon will be listed here.

Abstract

Malignant pleural effusions (MPEs) are the second leading cause of exudative pleural effusions after parapneumonic effusions. In the vast majority of cases, a MPE signifies incurable disease associated with high morbidity and mortality. Considerable advances have been made for the diagnosis of MPEs, through the development of improved methods in the specialized cytological and imaging studies. The cytological or histological confirmation of malignant cells is currently important in establishing a diagnosis. Furthermore, despite major advancements in cancer treatment for the past two decades, management of MPE remains palliative. This article presents a comprehensive review of the medical approaches for diagnosis and management of MPE.

Citing Articles

The Diagnosis of Malignant Pleural Effusion Using Tumor-Marker Combinations: A Cost-Effectiveness Analysis Based on a Stacking Model.

Wang J, Zhou J, Wu H, Chen Y, Liang B Diagnostics (Basel). 2023; 13(19).

PMID: 37835879 PMC: 10572148. DOI: 10.3390/diagnostics13193136.

Lung Cancer: Spectral and Numerical Differentiation among Benign and Malignant Pleural Effusions Based on the Surface-Enhanced Raman Spectroscopy.

Kowalska A, Czaplicka M, Nowicka A, Chmielewska I, Kedra K, Szymborski T Biomedicines. 2022; 10(5).

PMID: 35625729 PMC: 9138770. DOI: 10.3390/biomedicines10050993.

Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world.

Pan P, Wu F, Xu Z, Ji X, Qi Q, Huang X Thorac Cancer. 2021; 12(24):3416-3425.

PMID: 34741494 PMC: 8671907. DOI: 10.1111/1759-7714.14224.

Systemic Inflammatory Response to Different Sclerosing Agents as a Predictor of Pleurodesis Outcome.

Zablockis R, Danila E, Gruslys V, Cincileviciute G In Vivo. 2021; 35(4):2391-2398.

PMID: 34182522 PMC: 8286524. DOI: 10.21873/invivo.12516.

Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients: A multicenter retrospective study.

Roh J, Ahn H, Kim I, Son J, Seol H, Kim M Medicine (Baltimore). 2021; 100(19):e25748.

PMID: 34106603 PMC: 8133234. DOI: 10.1097/MD.0000000000025748.

References

Davies H, Sadler R, Bielsa S, Maskell N, Rahman N, Davies R . Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med. 2009; 180(5):437-44. DOI: 10.1164/rccm.200811-1729OC. View

Tan C, Sedrakyan A, Browne J, Swift S, Treasure T . The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006; 29(5):829-38. DOI: 10.1016/j.ejcts.2005.12.025. View

Sriram K, Relan V, Clarke B, Duhig E, Yang I, Bowman R . Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncol. 2011; 7(6):737-52. DOI: 10.2217/fon.11.45. View

Ren S, Terman D, Bohach G, Silvers A, Hansen C, Colt H . Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest. 2004; 126(5):1529-39. DOI: 10.1378/chest.126.5.1529. View

Janssen J, Collier G, Astoul P, Tassi G, Noppen M, Rodriguez-Panadero F . Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007; 369(9572):1535-1539. DOI: 10.1016/S0140-6736(07)60708-9. View

Ryu J, Ryu S, Kim Y, Cho J, Lee H . What is the clinical significance of transudative malignant pleural effusion?. Korean J Intern Med. 2004; 18(4):230-3. PMC: 4531644. DOI: 10.3904/kjim.2003.18.4.230. View

Vaughan L, Sahn S . Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994; 120(1):56-64. DOI: 10.7326/0003-4819-120-1-199401010-00010. View

Loddenkemper R . Thoracoscopy--state of the art. Eur Respir J. 1998; 11(1):213-21. DOI: 10.1183/09031936.98.11010213. View

Chernow B, Sahn S . Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med. 1977; 63(5):695-702. DOI: 10.1016/0002-9343(77)90154-1. View

10.

Heffner J, Klein J . Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008; 83(2):235-50. DOI: 10.4065/83.2.235. View

11.

Porcel J . Pleural fluid biomarkers: beyond the Light criteria. Clin Chest Med. 2013; 34(1):27-37. DOI: 10.1016/j.ccm.2012.11.002. View

12.

Roberts M, Neville E, Berrisford R, Antunes G, Ali N . Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010; 65 Suppl 2:ii32-40. DOI: 10.1136/thx.2010.136994. View

13.

Puri V, Pyrdeck T, Crabtree T, Kreisel D, Krupnick A, Colditz G . Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg. 2012; 94(2):374-9. PMC: 3783957. DOI: 10.1016/j.athoracsur.2012.02.100. View

14.

Ryu J, Ryu H, Lee S, Memon A, Lee S, Nam H . Prognostic impact of minimal pleural effusion in non-small-cell lung cancer. J Clin Oncol. 2014; 32(9):960-7. DOI: 10.1200/JCO.2013.50.5453. View

15.

Uzbeck M, Almeida F, Sarkiss M, Morice R, Jimenez C, Eapen G . Management of malignant pleural effusions. Adv Ther. 2010; 27(6):334-47. DOI: 10.1007/S12325-010-0031-8. View

16.

Maskell N, Gleeson F, Davies R . Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet. 2003; 361(9366):1326-30. DOI: 10.1016/s0140-6736(03)13079-6. View

17.

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

18.

Pass H, Levin S, Harbut M, Melamed J, Chiriboga L, Donington J . Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012; 367(15):1417-27. PMC: 3761217. DOI: 10.1056/NEJMoa1115050. View

19.

Liang Q, Shi H, Qin X, Liang X, Jiang J, Yang H . Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax. 2007; 63(1):35-41. DOI: 10.1136/thx.2007.077958. View

20.

Davies H, Mishra E, Kahan B, Wrightson J, Stanton A, Guhan A . Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA. 2012; 307(22):2383-9. DOI: 10.1001/jama.2012.5535. View